Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Call Transcript
Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.44 EPS, expectations were $-0.49.
Novavax Inc (NVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Shah Capital Management Himanshu H. Shah | 7,780,756 | $37,347,629 | +23% | 9.56% |
| 2. | Coatue Management Philippe Laffont | 1,519,594 | $7,294,051 | 0.03% | |
| 3. | 1,471,600 | $7,063,680 | 0.08% | ||
| 4. | 1,023,200 | $4,911,360 | -20% | 0% | |
| 5. | 1,400,000 | $4,755,000 | +8% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | Officer | 14,473 | 2023-03-10 | Filing | |
| $7.04 | 2,000 | Officer | 13,473 | 2023-03-07 | Filing | |
| $7.48 | 3,000 | Officer | 11,473 | 2023-03-06 | Filing | |
| $139.64 | 700 | Director | 2,800 | 2021-05-19 | Filing | |
| $48.83 | 1,500 | Director | 1,500 | 2020-06-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.10 | 300 | Director | 62,590 | 2022-03-31 | Filing | |
| $74.25 | 3,255 | Director | 62,890 | 2022-03-31 | Filing | |
| $73.29 | 8,945 | Director | 66,145 | 2022-03-31 | Filing | |
| $144.43 | 100 | Officer | 3,845 | 2022-01-03 | Filing | |
| $143.64 | 1,003 | Officer | 3,945 | 2022-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,775,875 | $80,524,200 | 0% | |
| 2. | 14,560,061 | $69,888,293 | 0% | |
| 3. | 8,436,179 | $40,493,660 | 0% | |
| 4. | 7,241,455 | $34,758,985 | 0% | |
| 5. | 2,297,507 | $11,029,665 | 0% |
News See All
Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Call Transcript
Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.44 EPS, expectations were $-0.49. Novavax, Inc.
Novavax, Inc. (NASDAQ:NVAX) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Novavax Third Quarter 2023 Financial Results and Operational Highlights Conference Call.
5 Most Shorted Stocks Right Now
Biomea Fusion, Inc. (NASDAQ:BMEA) is a biotechnology firm seeking to treat cancer and diabetes.
Novavax, Inc. (NASDAQ:NVAX) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome to the Novavax Second Quarter 2023 Financial Results and Operational Highlights Conference Call.
Billionaire Investor Who Returned 51% in 2022 is Selling These 12 Stocks in 2023
In this article, we discuss 12 stocks billionaire Chris Rokos is selling in 2023.
12 COVID-19 Treatment Stocks Hedge Funds Are Betting On
When most people think about living during a once in a lifetime event, it mostly involves positive scenarios.
5 Best Covid Treatment Stocks to Buy Today
39 of the 943 hedge funds part of Insider Monkey's database had held a stake in the company during last year's fourth quarter.
Novavax, Inc. (NASDAQ:NVAX) Q3 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Novavax Third Quarter 2022 Financial Results and Operational Highlights. All participants will be in a listen-only mode.
10 Best Vaccine Stocks To Buy Now
One of the most defensive areas of the market is healthcare, and in 2022 when the markets are falling to new lows, healthcare is showing remarkable resilience and even signs of upside potential.
Billionaire Hedge Funds
